3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Active not recruiting
3
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Bevacizumab
14
Injections
13
Drug Therapy
10
Gemcitabine
9
toripalimab
8
venetoclax
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
Carboplatin
7
pembrolizumab
6
irinotecan sucrosofate
6
Temozolomide
6
HMPL-013
6
tislelizumab
5
sintilimab
5
fludarabine
5
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
5
Fluorouracil
5
Etoposide
5
Cisplatin
5
Biopsy
5
osimertinib
4
lenvatinib
4
Rituximab
4
Radiotherapy
4
Pemetrexed
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Not yet recruiting
×
navitoclax
×
Clear all
NCT05054465
2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2
Not yet recruiting
48 enrolled